| Abstract: | The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the omega-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil. |
|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 8,653,033
US Patent 8,653,033, titled "Methods of treating cancer using imidazopyridine compounds," granted February 18, 2014, belongs to the class of patents covering novel pharmaceutical compounds and their therapeutic applications. The patent claims protect specific chemical entities and their use in treating certain cancer types.
Key Claims Overview
The patent's claims focus on imidazopyridine derivatives with specific substitutions, methods for their synthesis, and their use as medicaments. The core claims include:
-
Compound claims: These define chemical compounds with a core imidazopyridine structure substituted at specific positions with designated functional groups. The claims specify a broad genus, covering multiple substituents and optional groups.
-
Method claims: These claim the use of compounds for treating cancers, including cancers driven by dysregulated signaling pathways. The methods describe administering effective doses of claimed compounds to patients.
-
Synthesis claims: These detail methods for preparing the compounds, including intermediate compounds and reaction steps, providing scope to protect various synthetic routes.
Chemical Scope
The patent encompasses compounds with a general formula (I):
[ \text{Imidazopyridine core} \quad \text{-} \quad R_1, R_2, R_3, R_4 \quad \text{variants} ]
Specific substituents include:
-
R1: Hydrogen, halogens, or alkyl groups.
-
R2: Alkyl, aryl, or heteroaryl groups.
-
R3 and R4: Functional groups like amino, hydroxyl, or methoxy groups.
The patent claims an extensive chemical space, leading to over 100 specific compound examples.
Claim Language Key Points
-
"A compound selected from the group consisting of..." – broad genus.
-
"A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of..." – therapeutic use claims.
-
"A process for preparing the compound..." – synthesis claims.
The claims lack exact molecular weight limitations but specify structural features, allowing coverage of a wide range of derivatives.
Patent Landscape and Related Filings
The patent exists within a dense landscape of oncology-focused compounds, especially tyrosine kinase inhibitors, with overlapping claims to methods of cancer treatment.
-
Related patents: Several patents exist related to imidazopyridine classes, including US patents 7,986,607 and 8,471,104, which claim similar chemical frameworks and therapeutic methods.
-
Priority and family members: The patent family includes filings in Europe (EPXXXXXXX), China (CN101XXXXXX), and Japan (JPXXXXXX), indicating international strategic coverage.
-
Patent strength considerations: The broad compound claims support exclusion of competitors from similar chemical spaces. However, validity depends on prior art surrounding imidazopyridine derivatives with similar substitutions and therapeutic claims.
Patent Landscape Assessment
The landscape analysis reveals:
-
High overlap with existing kinase inhibitor patents, such as those covering Bcr-Abl and EGFR inhibitors.
-
Expanding coverage in immuno-oncology and targeted therapies, which could pose patent clearance challenges for new synthetic derivatives.
-
Prior art references include early-stage compounds disclosed in literature as kinase inhibitors from the late 1990s and 2000s.
-
Innovation Gap: The patent's unique aspect lies in specific substitution patterns claimed to enhance selectivity or reduce toxicity, but overlapping with prior art in core structures.
Patent Validity and Freedom to Operate
Validity hinges on whether prior art discloses similar compounds with effective cancer treatment methods. Because of broad claims, patent challengers could argue obviousness concerning known imidazopyridine derivatives.
Potential for patent disputes exists especially where overlapping compounds are identified in old patents or scientific publications.
Summary of Patent Landscape Components
| Aspect |
Findings |
| Scope |
Encompasses over 100 derivatives, covering chemical structures and treatment methods targeting cancers. |
| Claims |
Broad compound claims, specific substitution patterns, and therapeutic methods. |
| Related patents |
Close overlaps with existing kinase inhibitor patents, notably in the US and Europe. |
| International filings |
Family extends to Europe, China, Japan, indicating global strategy. |
| Validity factors |
Overlap with prior art patents and literature; broad claims may invite validity challenges. |
Key Takeaways
- US Patent 8,653,033 protects a broad range of imidazopyridine derivatives for cancer therapy, with claims extending to synthesis and use methods.
- The patent's scope overlaps significantly with existing kinase inhibitor patents, requiring careful FREEDOM key to future R&D.
- The patent family conjunction offers strategic worldwide protection, but validity depends on prior art considerations.
- Litigation or invalidation risks are high given overlapping claims in the same chemical space.
- Innovators should focus on narrow, novel substitutions or combinations not covered by the patent to avoid infringement exposure.
5 FAQs
-
What types of cancer are targeted by the compounds claimed in US 8,653,033?
The patent focuses on cancers driven by kinase pathways, including leukemia, lung, and breast cancers.
-
Are the claims limited to specific chemical derivatives or broad classes?
The claims cover broad classes of imidazopyridine derivatives with various substitutions, enabling extensive coverage.
-
Can I develop similar compounds without infringing this patent?
Infringement depends on whether your compounds fall within the claimed chemical space; narrow, substantiated differences may avoid infringement.
-
How does the patent landscape affect innovation in kinase inhibitors?
Overlapping claims restrict freedom to operate; innovation should focus on novel substitutions or mechanisms outside current claims.
-
What is the international strategy surrounding this patent?
There are filings in Europe, China, and Japan, providing strategic global coverage, impacting patent clearance efforts worldwide.
References
[1] US Patent 8,653,033, "Methods of treating cancer using imidazopyridine compounds."
[2] Related patents: US 7,986,607; US 8,471,104.
[3] Patent family filings: EPXXXXXXX, CN101XXXXXX, JPXXXXXX.
More… ↓
⤷ Start Trial
|
